Publication in accordance with art. 14 of the Belgian Law regarding the publication of major shareholdings (the "transparancy law")

 

Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from Bank of America Corporation on 5 July 2017.

Bank of America Corporation (taking into account the holdings of its subsidiary undertakings) notified Ablynx that they have dropped below the 5% threshold as of 28 June 2017 and now hold a total of 3,038,688 shares with voting rights, representing 4.97% of the current 61,133,199 outstanding Ablynx shares (versus 5.24% notified previously).

 

The notified details are presented below:

Name of select subsidiaries of

Bank of America Corporation

% of shares and voting rights

% of shares and voting rights held through financial instruments

 

Total of both

Shares

Voting rights

Shares

Voting rights

Shares

Voting rights

Merrill Lynch Professional Clearing Corp.

4.96%

4.96%

 

 

4.96%

4.96%

Merrill Lynch Financial Markets, Inc.

 

 

0.01%

0.01%

0.01%

0.01%

TOTAL

 

4.96%

4.96%

0.01%

0.01%

4.97%

4.97%

 

Merrill Lynch Professional Clearing Corporation and Merrill Lynch Financial Markets, Inc. are controlled by Bank of America Corporation. Bank of America Corporation is not a controlled entity.

 

Full versions of all transparency notifications are available on Ablynx website, under the section Investors.

Note

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 45 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie; Boehringer Ingelheim; Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA; Merck KGaA; Novartis; Novo Nordisk and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

 

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?